Abstract
Maintenance of hemostasis and pathological thrombus formation are physiological processes inextricably reliant upon intracellular signalling in platelets. The initial tethering of platelets to pro-thrombotic agents exposed at the site of injury triggers molecular events that culminate in activation of the major platelet integrin, αIIbβ3 (“inside-out” signalling). The ensuing conformational change and integrin clustering modulates the affinity of this receptor for its ligands, facilitating stable platelet adhesion and aggregation and triggering integrin αIIbβ3-dependent signalling pathways that control thrombus stability (“outside-in” signalling). Many of the signalling molecules regulating these processes have been elucidated by use of specific inhibitors and knock-out mouse models. However, dissection of this dynamic network is confounded by factors such as the emphasis on different pathways under different conditions and functional redundancies. Furthermore, physiologically, multiple receptors may be simultaneously stimulated and act synergistically to regulate thrombus formation. This review will discuss current concepts in αIIbβ3-mediated signalling in platelets, with a particular focus on the “outside-in” pathways triggered upon αIIbβ3 ligand engagement. Understanding the molecular networks controlling hemostasis and pathological thrombus formation will be important for the development of highly specific therapeutics that can avert disease states without resulting in bleeding diathesis.
Keywords: Integrin αIIbβ3, outside-in signalling, inside-out signaling, platelet thrombus formation
Current Signal Transduction Therapy
Title: Unravelling the Complicated Networks of Integrin αIIbβ3 Signalling in Platelets
Volume: 3 Issue: 3
Author(s): Karen S. Harris and Denise E. Jackson
Affiliation:
Keywords: Integrin αIIbβ3, outside-in signalling, inside-out signaling, platelet thrombus formation
Abstract: Maintenance of hemostasis and pathological thrombus formation are physiological processes inextricably reliant upon intracellular signalling in platelets. The initial tethering of platelets to pro-thrombotic agents exposed at the site of injury triggers molecular events that culminate in activation of the major platelet integrin, αIIbβ3 (“inside-out” signalling). The ensuing conformational change and integrin clustering modulates the affinity of this receptor for its ligands, facilitating stable platelet adhesion and aggregation and triggering integrin αIIbβ3-dependent signalling pathways that control thrombus stability (“outside-in” signalling). Many of the signalling molecules regulating these processes have been elucidated by use of specific inhibitors and knock-out mouse models. However, dissection of this dynamic network is confounded by factors such as the emphasis on different pathways under different conditions and functional redundancies. Furthermore, physiologically, multiple receptors may be simultaneously stimulated and act synergistically to regulate thrombus formation. This review will discuss current concepts in αIIbβ3-mediated signalling in platelets, with a particular focus on the “outside-in” pathways triggered upon αIIbβ3 ligand engagement. Understanding the molecular networks controlling hemostasis and pathological thrombus formation will be important for the development of highly specific therapeutics that can avert disease states without resulting in bleeding diathesis.
Export Options
About this article
Cite this article as:
Harris S. Karen and Jackson E. Denise, Unravelling the Complicated Networks of Integrin αIIbβ3 Signalling in Platelets, Current Signal Transduction Therapy 2008; 3 (3) . https://dx.doi.org/10.2174/157436208785699749
DOI https://dx.doi.org/10.2174/157436208785699749 |
Print ISSN 1574-3624 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-389X |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Medicinal Chemistry of Nitrite as a Source of Nitric Oxide Signaling
Current Topics in Medicinal Chemistry Pharmacodynamics and Pharmacokinetics of Antifungals for Treatment of Invasive Aspergillosis
Current Pharmaceutical Design Iron Chelating Strategies in Systemic Metal Overload, Neurodegeneration and Cancer
Current Medicinal Chemistry IP6 (Inositol Hexaphosphate) as a Signaling Molecule
Current Signal Transduction Therapy New Look at Therapeutic Strategies for Blocking Costimulatory Signal in Experimental and Pre-Clinical Transplantation
Current Drug Safety Contemporary Treatment of Amyloid Heart Disease
Current Pharmaceutical Design Mitochondria-Mediated Oxidative Stress: Old Target for New Drugs
Current Medicinal Chemistry Subcellular Analysis of the Platelet Proteome
Current Proteomics Perinatal Vitamin D Deficiency and Childhood Asthma: A Molecular Perspective
Current Respiratory Medicine Reviews Regulation of Endothelial Cell Death and Its Role in Angiogenesis and Vascular Regression
Current Neurovascular Research Advances in Peptide Pharmaceuticals
Current Pharmaceutical Biotechnology Radionuclide Liver Cancer Therapies: From Concept to Current Clinical Status
Anti-Cancer Agents in Medicinal Chemistry Human Carbonyl Reductases
Current Drug Metabolism Targeting Potassium Channels: New Advances in Cardiovascular Therapy
Recent Patents on Cardiovascular Drug Discovery Cardiovascular Disease and Inflammation: Novel Biomarkers of Inflammation and Endothelial Activation
Vascular Disease Prevention (Discontinued) Signaling Intermediates (PI3K/PTEN/AKT/mTOR and RAF/MEK/ERK Pathways) as Therapeutic Targets for Anti-Cancer and Anti-Angiogenesis Treatments
Current Signal Transduction Therapy Targeting Dyslipidemia in the Metabolic Syndrome: An Update
Current Vascular Pharmacology Serpins for Diagnosis and Therapy in Cancer
Cardiovascular & Hematological Disorders-Drug Targets Exercise-Induced Overexpression of Angiogenic Factors and Reduction of Ischemia / Reperfusion Injury in Stroke
Current Neurovascular Research Does Angiotensin Converting Enzyme Inhibitor Protect the Heart in Cardiac Surgery? From Laboratory to Operating Room: Clinical Application of Experimental Study
Current Pharmaceutical Design